News for Esperion Therapeutics, Inc. (ESPR)

ANN ARBOR, Mich., June 02, 2025 (GLOBE NEWSWIRE) -- Esperion ( ESPR) today announced that it has entered into a settlement agreement with Hetero USA, Inc. and

Esperion Therapeutics, Inc. (ESPR) has successfully resolved a patent dispute with Hetero USA, Inc. and its related entities, including Hetero Labs Limited, Het

Esperion (ESPR) has finalized a settlement with Micro Labs USA, Inc. and its affiliate, resolving a patent lawsuit initiated by Esperion. This legal action was

ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion ( ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc.

ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion ( ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3r

**media[620327]**

Esperion (ESPR) has awarded 49,300 restricted stock units (RSUs) to 15 new employees under its 2017 Inducement Equity Incentive Plan. The RSUs will vest

**media[619718]**

**media[618706]**

On May 7, 2025, Needham analyst Serge Belanger released an updated assessment on Esperion Therapeutics (ESPR), maintaining the stock's

Total Revenue: $65 million for Q1 2025, a 63% year-over-year increase after adjusting for a onetime milestone in Q1 2024.US Net Product Revenue: $34.9 million,

May 06, 2025 / 12:00PM GMTOperator Ladies and gentlemen, thank you for standing by, and welcome. (Operator Instructions) Please be advised that today's conferen

VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. ( CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CC

Esperion Therapeutics (ESPR) to present at the Citizens Life Sciences Conference on May 8, 2025. The company's FDA-approved non-statin medicines address

Japan-based Linkage Global Inc (LGCB) is up over 24 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

ANN ARBOR, Mich., April 23, 2025 (GLOBE NEWSWIRE) -- Esperion ( ESPR) today announced it will report first quarter 2025 financial results before the market op

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Key Highlights: Esperion Therapeutics (ESPR) stock has declined significantly, falling 15.8% in the past month.Despite a Momentum Score of A, a Hold ranking per

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.